about
Dissecting the indirect effects caused by vaccines into the basic elementsVaccination against herpes zoster in developed countries: state of the evidenceHerpes zoster-related hospitalizations and expenditures before and after introduction of the varicella vaccine in the United StatesRecommendations for the Management of Herpes ZosterVaricella and herpes zoster in Madrid, based on the Sentinel General Practitioner Network: 1997-2004.Epidemiology of herpes zoster infection among patients treated in primary care centres in the Valencian community (Spain).Sociodemographic characteristics and chronic medical conditions as risk factors for herpes zoster: a population-based study from primary care in Madrid (Spain)Impact of varicella vaccine on varicella-zoster virus dynamicsAssessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands.Systematic review of incidence and complications of herpes zoster: towards a global perspective.Herpes zoster and postherpetic neuralgia surveillance using structured electronic data.Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination.Ocular involvement and visual outcome of herpes zoster ophthalmicus: review of 45 patients from Tunisia, North Africa.Presentation and management of herpes zoster (shingles) in the geriatric population.Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve.Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.Herpes Zoster Risk Reduction through Exposure to Chickenpox Patients: A Systematic Multidisciplinary ReviewLong-term persistence of zoster vaccine efficacyEpidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the Valencian community of Spain.Comparing shingles incidence and complication rates from medical record review and administrative database estimates: how close are they?Chickenpox exposure and herpes zoster disease incidence in older adults in the U.S.The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study.Survey on public awareness, attitudes, and barriers for herpes zoster vaccination in South KoreaDisease Burden Due to Herpes Zoster among Population Aged ≥50 Years Old in China: A Community Based Retrospective SurveyShould the UK introduce varicella vaccine?Coverage, efficacy or dosing interval: which factor predominantly influences the impact of routine childhood vaccination for the prevention of varicella? A model-based study for Italy.The temporal impact of aging on the burden of herpes zoster.A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax.Immunogenicity and Safety of a Live Attenuated Zoster Vaccine (ZOSTAVAX™) in Korean Adults.Incidence of herpes zoster ophthalmicus: results from the Pacific Ocular Inflammation Study.Asthma as a risk factor for zoster in adults: A population-based case-control study.Epidemiology of Herpes Zoster Ophthalmicus: Recurrence and ChronicityThe epidemiological, clinical, and pathological rationale for the herpes zoster vaccine.Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zosterCost-effectiveness of varicella vaccination programs: an update of the literature.Hospitalizations to treat herpes zoster in older adults: causes and validated rates.Influence of frequent infectious exposures on general and varicella-zoster virus-specific immune responses in pediatricians.Incidence of herpes zoster in patients with altered immune function.Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy.Examination of links between herpes zoster incidence and childhood varicella vaccination.
P2860
Q26799527-214C454B-1A38-4CB2-9898-58688D96B433Q26862748-092C70A8-3350-49A5-8F45-9E67178888D8Q28300462-4BC9F61B-17E6-4C2B-BF46-9636D5C8864EQ28315869-DCB03C39-6429-41C1-B657-30A43F4B0B96Q33287811-82706869-A0A0-4656-B028-2D9ED1F049C9Q33574978-9CDF0E6C-31EA-4236-B680-D9E5C3147EC1Q33578057-F81EADDB-9903-49DF-BD1B-6A02816C05F4Q33591264-B8A5B8D3-8AC1-493E-877B-16185C2499E9Q33657323-781ECE45-F452-4D95-9904-BA446B2E46E7Q33795551-6B032857-C797-4FDA-80F5-75A8E7131799Q34047979-4F1B4BC2-52DF-4360-9BD3-48E857641288Q34158156-265C3AF4-C426-4A41-A4FF-274D4CB15DB2Q34212844-31A17D70-5F8E-4908-B1BE-F19EB474FC84Q34352218-D28DF1B7-4455-450E-B228-866F505219C2Q34430200-FB315CD8-FEBC-4864-977B-A7435B290D10Q34635527-BE333819-5860-47B0-BBB8-15A7612612C7Q34785366-5D12B00E-AAAC-400A-873B-32B62A07B5B6Q35171857-56DE3CDC-1A45-48ED-B109-9D915740B5C0Q35607755-257943CD-9F5D-4E94-8934-25117A8B77E8Q35627422-BDC924EA-A45A-481B-ADD4-E0C27B347FE4Q35676115-2AC269ED-2575-45A5-950A-77FE482E6635Q35840824-1A040988-9642-457F-921D-66E151CD1754Q35887427-95875CA1-18C0-4110-8F43-74BC4EEEACC0Q35982768-C1392530-1EAD-4BB6-B11B-DA27EF4E42A1Q36121450-D7F2E14F-3E6C-4C69-A8FB-3871E0B50BB1Q36171295-47BB11C4-8B1C-4A70-8201-03B4A7350586Q36257901-0BEC9EF9-4AC9-4DA8-837D-5EBB177AF83BQ36452320-36AE2E8E-20B1-43E7-BE19-2C5C9EE33085Q36461527-C4E5660D-F030-4B86-94CA-6B81F5349257Q36674803-118FD931-D9E4-472B-9670-F51C463CA333Q36880196-06A750D1-B5EB-4F9F-945F-8D5B214CDA9DQ37038580-EA3C6E22-BDDC-45B0-B9C2-B4A093E0F006Q37141163-B6B74F52-6DB2-44A7-B964-492E77BD507AQ37171211-620556F2-A9A8-46DA-B9D0-908789256695Q37229923-1E99D659-CA28-4FB4-A291-13610CC19D24Q37235263-ADD9D52B-C72F-4DBF-9785-FBADA99D8CB5Q37643309-44221369-B11F-49F2-B14C-5D59CB218AE4Q37670193-DB1C2C2A-E804-4B3A-A187-8D72A7B630BDQ38418892-175FC835-2FBF-415F-B746-C5E6CB4DF168Q38423324-54A8CB92-017F-481C-9A32-5F332A802B02
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Incidence of herpes zoster, 1997-2002.
@en
Incidence of herpes zoster, 1997-2002.
@nl
type
label
Incidence of herpes zoster, 1997-2002.
@en
Incidence of herpes zoster, 1997-2002.
@nl
prefLabel
Incidence of herpes zoster, 1997-2002.
@en
Incidence of herpes zoster, 1997-2002.
@nl
P2093
P1476
Incidence of herpes zoster, 1997-2002.
@en
P2093
P304
P356
10.1017/S095026880400281X
P577
2005-04-01T00:00:00Z